Sulfated glucosamine inhibits MMP-2 and MMP-9 expressions in human fibrosarcoma cells

In the present study, sulfated glucosamine (SGlc) that has been reported to relieve joint pain and inflammation in many arthritis patients was studied for its inhibitory effects on MMP-2 and MMP-9 in human fibrosarcoma cells. Expression and activity of above MMPs studied using gelatin zymography suggested SGlc as a potent MMP inhibitor. Further, transfection of promoter genes of MMPs and their transcription factors clearly exhibited that inhibition of MMP-2 and MMP-9 was due to down-regulation of transcription factor, NF-κB. However expression of activator protein-1 (AP-1), another important transcription factor of MMPs, was not affected by SGlc treatment. In addition, protein expression results of Western blot analysis were also in agreement with the results of gene transfection experiments. Moreover, down-regulation of NF-κB resulted in production of low levels of both NF-κB p50 and p65 proteins and directly affected activation process of MMP-2 and MMP-9 expressions. Since MMPs involve in joint inflammation, it can be presumed that inhibition of MMP-2 and MMP-9 can be one of the mechanisms of SGlc to be an effective drug in relieving the symptoms of osteoarthritis.

Sulfated glucosamine (SGlc) was prepared from glucosamine (Glc) and studied for its inhibitory effects on MMP-2 and MMP-9 in human fibrosarcoma (HT1080) cells. SGlc inhibited both MMP-2 and MMP-9 expressions by down-regulating their transcription factor NF-κB.Figure optionsDownload as PowerPoint slide